Jason Krynicki's Journey: From Obesity Bullying to Anorexia on GLP-1s
Jason Krynicki will never forget the vicious bullying he endured as a child due to his larger body size. Today, at age 43, he weighs a willowy 127 pounds, yet those painful memories persist. "You try to eat, and in the back of your mind, your mind still goes back to what people said to you 20 years ago," Krynicki says, recalling how other kids—and even doctors—called him fat and worse for his large appetite.
An insurance coordinator in Brick, NJ, Krynicki underwent bariatric surgery a decade ago. During the pandemic, he regained some weight, prompting his doctor to prescribe Zepbound, a GLP-1 injection. The drug stripped away 80 pounds—too much, leading to health issues like hair loss and light-headedness from low blood sugar. Despite an anorexia diagnosis, he fixates on losing more and weighs himself every other day. Meals spark internal conflict; he knows he needs to eat more to regain muscle but fears quitting: "I'm afraid that if I come off of it, I'm going to go back to that 267-pound person that had all the medical issues, hated his life and everything about myself."
The Rise of GLP-1 Drugs and Their Impact on Eating Behaviors
GLP-1 receptor agonists like Zepbound (tirzepatide) and others mimic the glucagon-like peptide-1 hormone, signaling fullness to the brain and slowing gastric emptying. This mechanism powerfully curbs appetite, driving significant weight loss in obesity treatment. However, for individuals prone to disordered eating, this suppression disrupts natural hunger cues, complicating nourishment.
Nearly a tenth of people will meet clinical benchmarks for an eating disorder in their lifetime, with far more experiencing problematic relationships with food and body weight. The surge in GLP-1 availability—often obtained online with minimal screening—amplifies vulnerabilities. Experts note little research exists on GLP-1 use or misuse in binge or restrictive eaters, despite these behaviors' prevalence.
Why GLP-1s Differ from Past Weight-Loss Drugs
Dr. Samantha DeCaro, who heads clinical outreach at The Renfrew Center specializing in eating disorders, compares GLP-1s to historical abuses like diet pills, appetite suppressants, diuretics, and enemas. "Today's GLP-1s are more powerful and wholly different," she says, warning they hinder regular nourishment and attunement to hunger signals. Weight loss rarely resolves underlying psychology; eating disorders involve emotional, relational, and biological drivers, often co-occurring with severe depression, anxiety, or PTSD.
Heavy marketing and celebrity endorsements revive a "cult of thinness," eroding body positivity. DeCaro notes grief over losing representation from larger-bodied influencers who once promoted acceptance.
Expert Warnings: Screening Gaps and High-Risk Groups
Most patients aren't evaluated for eating disorders before GLP-1 prescriptions, says Washington, DC psychologist Robyn Pashby, who serves on the Obesity Action Coalition board. "We're at a point where we need to hold two truths: That GLP-1s are legitimate evidence-based treatments for obesity, but that they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk," she emphasizes.
Psychiatrist Kim Dennis, CEO of SunCloud Health in Chicago, highlights dangers for those with low natural GLP-1 levels who binge due to poor satiety signals—GLP-1s might help here by restoring balance. However, misuse abounds. On the day she spoke, Dennis fielded a call about an anorexic patient with BMI 16 (e.g., a 5-foot-3 person at 90 pounds) obtaining drugs online by falsifying weight. She urged ER admission in a controlled setting.
